ERBB2 and neoplasm: Her2 can activate intracellular pathways that promote proliferation, survival, mobility and invasiveness of tumor cells and these aggressive oncogenic features translate into reduced survival in patients with Her2-overexpressing breast and gastric cancers11, 13.